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Abstract 
  
Background: Lymphocyte migration from the blood into the CNS is mediated by chemokines 
and chemokine receptors. Chemokines CXCL10 and CXCL11 are important for the 
recruitment of CXCR3-expressing Th1 lymphocytes to the site of inflammation.  
Aims: To determine the concentrations of CXCL10 and CXCL11 in the CSF and plasma of 
children with enteroviral aseptic meningitis (EV AM) and controls and the contribution of 
these chemokines to the chemokine concentration gradient between the periphery and the 
CNS.  
Methods: The study included 26 pediatric patients with EV AM and 16 controls in whom 
CNS infection is excluded by negative CSF examination. Chemokines were quantified by 
using enzyme immunoassay. Etiological diagnosis of EV AM was based on the detection of 
enteroviral RNA in the CSF using real-time PCR.  
Results: CXCL10 (median 12 725 pg/ml) and CXCL11 (median 187 pg/ml) concentrations in 
CSF of patients with meningitis were significantly higher compared to plasma (median 173 
pg/ml and median 110 pg/ml; p<0.001, p=0.026 respectively). CXCL10 concentrations in the 
CSF (median 198 pg/ml) and plasma of controls (median 124 pg/ml) were not significantly 
different (p=0.642). CXCL11 concentrations in the CSF of controls (median 89 pg/ml) were 
significantly lower compared with plasma (median 139 pg/ml, p=0.004). Chemokine 
concentration gradient was not influenced by pleocytosis, nor dependent on cytologic CSF 
formula or the presence of proteinorrachia. 
Conclusion: CXCL10 and CXCL11 concentration gradient between the CSF and plasma in 
children with EV AM suggests an important role of these chemokines in the T-cells 
recruitment into the CNS and local immunoreaction.  
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Introduction 
 
Enteroviruses (EV), RNA viruses belonging to Picornaviridae family,  causes  wide spectrum 
of illnesses, from benign and self-limiting diseases manifested by fever alone to severe life 
treatening infections, including neonatal sepsis, myocarditis, encephalitis and myelitis.1, 2, 3 
However, the most common clinical presentation of EV disease that deserves the attention of 
clinicians especially during the summer and fall season is aseptic meningitis (AM).1, 4 The 
importance of EVs in AM ethiology clearly underlines the fact that more than 80% of all AM 
cases in which the causative agent was defined are caused by one of those viruses.1 The 
widespread use of standardised real-time polymerase chain reaction (PCR) assays for 
ethiological diagnostics of neurotropic viruses in the cerebrospinal fluid (CSF) of patients 
with AM has further increased the number of diagnosed cases and thus confirmed the leading 
position of EVs in the ethiology of this syndrome.1 Although the clinical characteristics and 
laboratory findings in EV AM have been well studied, the knowledge of the local immune 
response is still scarce.1, 4 - 6 The majority of studies dealing with this topic have focused on 
patients with more severe forms of CNS inflammation caused by EVs, especially those with 
enterovirus 71 (EV71) brain stem encephalitis.7, 8 
The leading, although nonspecific laboratory hallmark of EV AM is pleocytosis, usually 
predominantly lymphocytic.4 Some earlier studies demonstrated a preferential recruitment of 
memory CD4+ T-cells from the blood to the CSF.5, 9, 10 These results support the hypothesis 
that activated memory CSF CD4+ T-cells are the principal cellular subpopulation responsible 
for the local immune response in patients with inflammatory CNS diseases, including those 
with EV AM.5 
After crossing the blood brain barrier (BBB) memory CD4+ T cells can encounter and 
recognize their specific antigen and trigger the local inflammatory response. Alternatively, in 
case that memory CD4+ T cells do not encounter an antigen, they will recirculate back into 
the periphery.11 
The lymphocyte migration through the BBB into the CSF in response to infection with 
neurotropic viruses is mediated by chemokines and their corresponding receptors.12 
Chemokines are small, soluble, basic proteins that can be classified into four subfamilies: 
CXC, CC, CX3C and C, depending on the number and distribution of cystein residues within 
the amino terminus of the molecule.13 The current hypothesis holds that upon recognition of 
viral DNA or RNA, Toll-like receptors activate intracellular signaling cascade resulting in 
enhanced expression of genes coding for various cytokines, particularly interferons and 
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chemokines.14 In vitro and in vivo studies showed that astrocytes and microglia cells are the 
principal sources of chemokines following viral infections of the CNS. Studies in both animal 
and human models showed complex and variable patterns of chemokine synthesis in various 
CNS viral infections.14  
Chemokines CXCL10 (interferon-inducible protein-10, IP-10) and CXCL11 (interferon-
inducible T-cell alpha chemoattractant) are CXC chemokines that are synthesised upon 
stimulation with IFN-γ during infection or inflammation.11 Both chemokines bind to the 
chemokine receptor CXCR3 and are important in pathologies mediated by activated Th1 
CD4+ T-cells. The biological role of CXCL10 appears to be complex. CXCL10 recruits 
antigen-specific activated CXCR3-positive T-cells into the CNS enabling the efficient control 
of viral replication.13 However, persistent overexpression of CXCL10 can lead to continuous 
infiltration of inflammatory cells that can subsequently lead to neurotoxicity, cell death or an 
immune-mediated demyelinating disease.14-16  
Several studies investigated the expression of CXC10 and CXCL11 as well as possible 
contribution to the immunopathogenesis of CNS infections caused by tick-borne encephalitis 
virus, West Nile virus, lymphocytic choriomeningitis virus, human immunodeficiency type 1 
virus, herpes simplex virus and neuroborreliosis in adult patients.17-23 However, literature data 
on the expression of these chemokines in pediatric viral CNS infections are scarce. The 
Taiwanese investigators demonstrated the presence of CXCL10 in the CSF of children with 
brainstem encephalitis developing as a consequence of infection with enterovirus 71.8 To our 
knowledge, the expression of CXCL10 and CXCL11 in the CSF of Caucasian children with 
non-complicated clinical course of EV AM has not been previously investigated. 
The aim of this study was to investigate the presence of CXCL10 and CXCL11 in the CSF 
and plasma of children with EV AM and compare the observed pattern of expression with 
controls in whom the diagnosis of CNS inflammatory disease was excluded. The results of 
this study are expected to determine whether overexpression of CXCL10 and/or CXCL11 in 
the CSF contributes to the induction of local cellular immune response in patients with EV 
AM.  
Additionally, extensive research on the role of chemokines in the pathogenesis of various 
inflammatory diseases consequently lead to the development of a large number of molecules 
targeting chemokines and chemokine receptors as candidates for human therapeutics. So far, 
two drugs targeting chemokines and chemokine receptors are currently in use; a CCR5 
inhibitor for the treatment of HIV-infection and a CXCR4 antagonist that stimulated 
hematopoietic stem cell mobilisation that is essential for the treatment of hematological 
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malignancies.24 Therefore, the results of this study can provide an important insight into 
possible relevance of chemokine/chemokine receptor inhibitors/antagonists as potential 
therapeutics in the treatment of inflammatory CNS diseases. 
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Patients and methods 
 
Study design and patients:  
 
This prospective, cross-sectional study was carried out at the University Hospital for 
Infectious Diseases „Dr. Fran Mihaljevic“ (UHID), Zagreb, Croatia between January 2009 
and November 2010. The study included 42 patients aged less than 14 years of whom 26 with 
EV AM, and 16 controls. The diagnosis of AM was based on clinical signs and symptoms, 
accompanied with CSF cytological and biochemical findings, negative Gram stain and 
bacteriological culture.25 The EV ethiology was confirmed using real-time PCR. The control 
group of patients consisted of children with clinical suspicion of CNS infection at the 
admission to the hospital, but in whom the initial diagnosis was ruled out based on negative 
CSF cytology, bacteriological analysis, as well as the exclusion of EV infection using 
panenteroviral real-time PCR. In all patients included in the control group an extraneural site 
of infection was subsequently proved. The final diagnosis were as follows: streptococcal 
pharyngitis,  pneumonia and viral gastroenteritis - four patients per diagnosis, while influenza 
A and urinary tract infection were diagnosed in three and one patient, respectively.   
The Ethics Committee of the UHID approved this study and informed consent was obtaied 
from all parents or custodians. 
 
Samples: 
 
Chemokines CXCL10 and CXCL11 were quantified in CSF and plasma samples collected on 
the same day in all patients and controls. All samples for analysis were taken within 24 hours 
after the admission. CSF samples (volume between 400-1000 µL) were collected by lumbar 
puncture (LP) and stored at -80ºC untill testing in two aliquots to avoid repeated freeze and 
thaw cycles. Plasma obtained from peripheral blood samples collected with K3EDTA was als 
o stored at -80ºC until analysis.  
The number of cells per µl of CSF was determined by counting in a Fuchs-Rosenthal 
chamber. CSF sediments were prepared by using a Shandon Cytospin 3 (Life Sciences 
International Europe, Astmoor, Runcorn, Cheshire, UK) for 5 min. at 300g. One CSF 
sediment sample was stained with My-Grunwald-Giemsa stain for routine cytological 
analysis. Percentages of granulocytes, lymphocytes and monocytes were determined after 
analyzing 200 cells in the sediment. Biochemical analysis was performed by using Beckman 
Coulter AU640 (Beckman Coulter, Fullerton, CA, USA).  
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Chemokine quantification 
 
Concentrations of CXCL10 and CXCL11 in the CSF and plasma of patients as well as 
controls were determined by using standardised enzyme immunoassays Quantikine Human 
CXCL10/IP-10 ELISA and Quantikine Human CXCL11 ELISA (R&D Systems, 
Minneapolis, USA).  
 
 
Etiological diagnostics 
 
Detection of pan-enteroviral RNA in the CSF of all patients and controls was performed by 
using real-time PCR. RNA was extracted from the 200 µL of CSF by using QIAamp Viral 
RNA Mini Kit (Qiagen, Hilden, Germany). The presence of EV RNA was determined by 
using Cepheid Analyte Specific Reagent (ASR) EV assay on real-time PCR SmartCycler 
instrument (Cepheid, Sunnyvale, CA, USA). Cepheid ASR EV assay contains FAM-labeled 
and Alexa 532-labeled probe that are designed to detect a 115 bp sequence of the highly 
conserved 5'untranslated region (UTR) of EVs.  
 
Statistical analysis 
Kolmogorov-Smirnov test was used to test the normality of quantitative data. Comparison 
between the two independent groups was made with nonparametric Mann-Whitney U test 
while the Wilcoxon signed ranks test was used for paired data. Fisher exact test was used for  
categorical data and correlation between quantitative data was determined using Pearson 
correlation coefficient. Statistical significance was determined at the 0.05 level. Statistical 
analysis was performed by using SPSS (Statistical Package for Socal Sciences) version 13.5 
(SPSS Inc., Chicago, IL, USA).   
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Results 
 
There were 42 patients included in the study, of whom 26 (61.9%) with confirmed EV AM 
and 16 (38.1%) in the control group. In EV AM group there were 17 (65,4%) males, while in 
the control group males represented 62,5% of all patients. The median age of patients in the 
EV AM group was 72.0 months (range: 1-168 months) whereas in the control group the 
median age of patients was 31.5 months (range: 3-132 months). Comparing the main 
characteristics (sex, age) between EV AM and control group, no statistical difference was 
found (p>0.999 and p=0.140, respectively) (Table 1.). The differences were also not found 
comparing the day of illness when LP was done, maximum fever, as well as peripheral white 
blood cell (WBC) count, while there were  statistically significant differences in comparison 
of C-reactive protein (CRP) concentrations in plasma, the amount of pleocytosis as well as 
CSF protein concentrations between the two groups (Table1.)  
 
Concentrations of CXCL10 in the CSF of patients with EV AM (median 12 725 pg/ml, range 
235-174 439 pg/ml) were significantly higher compared to those from the corresponding 
plasma samples (median 173 pg/ml, range 8-5 192 pg/ml) (p<0.001). CXCL10 concentrations 
in the CSF (median 198 pg/ml, range 21-436 pg/ml) and plasma (median 124 pg/l, range 43-
686 pg/ml) of patients from the control group were not significantly different (p=0.642).  
 
Similarly, concentrations of CXCL11 in the CSF of patients with EV AM (median 187 pg/ml, 
range 0-6272 pg/ml) were significantly higher in comparison to plasma concentrations 
(median 110 pg/ml, range 52-937 pg/ml) (p=0.026). Contrary to CXCL10 pattern of 
expression, CXCL11 concentrations in the serum of patients from the control group (median 
139 pg/ml, range 71-1969 pg/ml) were higher compared to their corresponding CSF 
concentrations (median 89 pg/ml, range 0-274 pg/ml) (p=0.004). Data on CXCL10 and 
CXCL11 concentrations in patients with EV AM and controls are shown in Figure 1.  
 
Analysing the possible contribution of amount of pleocytosis on chemokine concentrations in 
the CSF, the positive correlation were not found for CXCL10 and CXCL11 in patients with 
EVAM (r=-0.142, p=0.488 and r=-0,100, p=0.961, respectivelly) nor in patients from the 
control group (r=0,444, p=0.085 and r=0.134, p=0.621, respectivelly). The comparison of 
CXCL10 and CXCL11 concentrations in patients with EV AM in relation to cytologic CSF 
formula (polynuclear vs lymphocytic predominance), as well as in relation to 
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abscence/presence of proteinorrachia (cut off value 450 mg/L) was also done. We found no 
difference in CXCL10 and CXCL11 concentrations among those groups of patients (Table 
2.).  
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Discussion 
 
The results of this study showed, for the first time, that CSF of children with EV AM 
contains chemokines CXCL10 and CXCL11. This study demonstrated increased 
concentrations of CXCL10 and CXCL11 in the CSF of patients with EV AM compared with 
plasma as well as the absence of such concentration gradient in patients from the control 
group.  
 CXCL10 is a CXCR3-ligand that enables recruitment of activated T-cells to sites of 
immune reactions, mostly inflammation. The prerequisite for the migration of CXCR3-
positive cells to sites of inflammation is the concentration gradient of CXCL10. Several 
studies conducted on animal models as well as in adult patients with neurotropic viral 
infections showed increased expression of CXCL10 in the CNS/CSF compared with 
peripheral blood. 17-21  
To our knowledge, the only study on chemokine expression in the CSF of pediatric 
patients with enteroviral CNS infection was published in 2008 by Wang et al.8 The study 
conducted in Taiwan focused on expression of CXCL10, CXCL9, CCL5, CCL2 and 
interleukin-8 in the CSF and plasma of children with brainstem encephalitis (BE), a serious 
neurological manifestation of EV71 infection.8 Increased levels of CXCL10, CXCL9, CCL2 
and IL-8 in the plasma of children with pulmonary edema (PE) versus uncomplicated BE 
demonstrated an association between the extent of chemokine response and clinical 
presentation of disease.8 The results of our study can not be directly compared with Wang's 
mainly due to the fact that our study enrolled children with uncomplicated AM associated 
with various EVs (not limited to EV71). However, contrary to our results, a concentration 
gradient between CSF and plasma concentrations of CXCL10 was not observed in children 
with BE caused by EV71 irrespective of clinical presentation (uncomplicated BE, autonomic 
nervous system dysregulation and PE). The observed difference confirms previous findings 
on distinct chemokine signature patterns observed in CNS viral infections.14  
The presence of CXCL10 concentration gradient between the CSF and plasma of 
children with EV AM supports the concept that CXCL10 might act as a chemoattractant for 
antigen-specific activated T-cells and play an important role in their recruitment into the CSF. 
This hypothesis can be indirectly confirmed by observing a different pattern of CXCL10 
expression (no difference in CSF/plasma concentrations) in controls, e.g. children in whom 
the initial clinical diagnosis of CNS inflammation was subsequently excluded. To our 
knowledge, our study is the first to provide experimental evidence on CXCL10 and CXCL11 
12 
 
quantification in the CSF of pediatric controls (only plasma concentrations were reported in 
other studies).14  
Literature data on CXCL11 expression in the CSF of patients with inflammatory and 
non-inflammatory CNS diseases are limited to TBE, neuroborreliosis and multiple sclerosis 
(MS)17, 22, 23, 26, 27 Rupprecht et al. showed significantly higher expression of CXCL10 in the 
CSF of patients with neuroborreliosis compared with controls as well as a correlation between 
CXCL11 levels and CSF-white cell counts.23 More recently, Szczucinki et al. found no 
difference in the levels of CXCL11 in the CSF of patients with active or stable relapsing-
remitting multiple sclerosis (MS) compared with controls.26 However, in Mellergard's study a 
significant decline in CSF CXCL10 concentrations in MS patients after one year of 
natalizumab treatment was observed.27 Our study provides the first experimental evidence on 
the CXCL11 concentration gradient between the CSF and plasma in patients with EV AM. 
The severity of local inflammation and degree of BBB dysfunction which were in our patients 
measured only indirectly through the analysis of total CSF cell count, CSF polynuclear 
predominanceand the presence/abscense of proteinorachia probably has no impact on 
chemokine gradient existence. However, further studies are needed prior to final conclusion 
could be done.  
Additionally, studies on the expression of selected chemokines in patients with non-
complicated clinical course of EV AM versus patients with adverse clinical course might help 
establish a rationale for anti-chemokine therapy in severe enteroviral CNS infections, 
especially encephalithic forms of disease and possibly other inflammatory CNS diseases in 
the future.  
In conclusion, this study demonstrated the presence of CXCL10 and CXCL11 
concentration gradient between the CSF and plasma in children with uncomplicated clinical 
course of EV AM suggesting an important role of these chemokines in the recruitment of T-
cells into the CNS and local immune response to EV. 
Further studies on a greater number of patients including those with encephalitic form 
of disease are nedeed. In case similar findings are reached, it could be a further support to the 
hypothesis that chemokines/chemokines receptors may serve as therapeutical targets in severe 
forms of viral CNS diseases as well as possible surrogate markers in predicting the severity of 
disease.  
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Table 1 - Main clinical and laboratory characteristics of patients with enteroviral aseptic 
meningitis (EV AM) and controls 
 
Parameter 
 
EV AM Controls p-value 
Sex 
 
17 M; 9 F 10 M; 6 F >0.999 
Age in months; 
median (range) 
 
72.0  
(1 – 168) 
31.5 
(3 – 132) 
0.140 
Day of illness when 
LP was performed; 
median (range) 
2.0 
(1.0 – 4.0) 
2.0 
(1.0 – 5.0) 
0.718 
Maximum fever in 
ºC; median (range) 
 
38.3 
(37.6 – 40.0) 
38.9 
(37.0 – 39.8) 
0.231 
CRP in mg/L; 
median (range) 
  
4.35 
(0.2 – 23.8) 
10.7 
(0.2 – 144.9) 
0.029 
WBC x 109/L; 
median (range) 
 
12.1 
(5.5 – 27.8) 
12.5 
(2.5 – 56.5) 
0.400 
CSF pleocytosis 
cells/µL; median 
(range)  
130.5 
(90.0 – 2386.0) 
3.0 
(1.0 – 6.0) 
<0.001 
CSF proteins mg/L; 
median (range)  
528 
(230 – 1034) 
236 
(185 – 615) 
<0.001 
 
- LP, lumbar puncture; WBC, white blood cells; CSF, cerebrospinal fluid 
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Table 2 - CXCL10 and CXCL11 concentrations in different subgroups of patients with 
enteroviral aseptic meningitis (EV AM) 
 
 
Chemokine 
Cerebrospinal fluid formula p-
value 
CSF protein concentration 
 
p-
value PML<50% PML≥50% 
<450 mg/L ≥450 mg/L 
CXCL10 
pg/mL; 
median 
(range) 
13878 
(235–75439) 
10930 
(3189–102090) 
0.470 15402 
(1637– 
27823) 
11251 
(235–
175439) 
0.712 
CXCL11 
pg/mL; 
median 
(range) 
187 
(0-6282) 
188 
(99 – 6126) 
0.795 153 
(70– 1613) 
211 
(0 – 6272) 
0.617 
 
- PML, polymorphonuclear leukocytes 
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Figure 1. Concentrations of CXCL10 and CXCL11 in the cerebrospinal fluid of children with 
enteroviral aseptic meningitis and controls 
 
Figure 1. Concentrations of CXCL10 (log10 pg/ml) and CXCL11 (log10 pg/ml) in
the cerebrospinal fluid of children with enteroviral aseptc meningitis (EVAM) and
controls. In two patients in the control group and one in the EVAM group, CXCL11
was not detected and these measurments are excluded from the graph. The
horizontal line is the median value.
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